Journal
NANO LETTERS
Volume 17, Issue 7, Pages 4421-4426Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.nanolett.7b01518
Keywords
Lab-on-chip; all-dielectric nanoresonators; biosensing cancer; silicon
Categories
Funding
- European Community's Seventh Framework Program under grant QnanoMECA [64790]
- Fundacio Privada Cellex
- Spanish Ministry of Economy and Competitiveness, through the Severo Ochoa Programme for Centres of Excellence in RD [SEV-2015-0522, FIS2016-80293-R]
- Swedish Research Council [637-2014-6894]
Ask authors/readers for more resources
Nanophotonics has become a key enabling technology in biomedicine with great promises in early diagnosis and less invasive therapies. In this context, the unique capability of plasmonic noble metal nanoparticles to concentrate light on the nanometer scale has widely contributed to biosensing and enhanced spectroscopy. Recently, high-refractive index dielectric nanostructures featuring low loss resonances have been proposed as a promising alternative to nanoplasmonics, potentially offering better sensing performances along with full compatibility with the microelectronics industry. In this letter we report the fitst demonstration of biosensing with silicon nanoresonators integrated in state-of-the-art microfluidics. Our lab-on-a-chip platform enables detecting Prostate Specific Antigen (PSA) cancer marker in human serum with a sensitivity that meefs clinical needs. These performances are directly compared with its plasmonic counterpart based on gold nanorods. Our work opens new opportunities in the development of future point-of-care devices toward a more personalized healthcare.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available